The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Exactly DSFlat. This would have been a great time for Stalicla to dump SFX-01 if they had any intention to. However, they have instead updated their guidance and reaffirmed that they are planning for STP2 to enter phase 2 trials this year.
We know that before Phase 2 trails can commence, IND is needed from the FDA so this MUST be applied for, and not objected to, before trials can commence. Within 30 calendar days of application we will know if IND has been accepted as after 30 days approval is automatic - the FDA have 30 days to object, although all available safety data for SFX-01 would suggest no objections should occur.
We also know that Stalicla will be due to pay Evgen $5m on approval of IND. Therefore, it is reasonable to presume that Evgen will receive the monies due before cash runs out towards the end of the year, avoiding the need for any placement.
"STP2 will enter Phase 2 in 2024"
Is what Stalicla Website states...
https://stalicla.com/pipeline
Someone knows something.
There are a lot of people who think the Stalicla money is coming any time now, some even suggested this week. I would be very surprised, the last update by EVG two weeks ago stated:
The companies are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future Phase 2 trial in ASD
Anyone who thinks that will be done in a couple of weeks has rocks in their head and should go and see a psychiatrist, they are mental.
I've also only just spotted that your £5.7 billion pound valuation and £41 a share doesn't add up. Clearly mathematics is not your strong suit, and neither is science, or investing for that matter.
You claimed £5.7 billion valuation is equivalent to £41 a share, but with just over 200 million shares in issue for OBD this doesn't make sense. Oh dear oh dear.
Taking a number and dividing is simple, but still you managed to mess it up Kingalf.
I have no clue who money munch is, however, they clearly got under your skin. If you search, you will see that the account you are referring to is still very much active with the last post on the 22nd of Jan 2024, albeit they are invested in a different share from the looks of it. You would also note the writing style between this other account and myself is vastly different. They seem to copy and paste a lot which I do not do, while the language we use is also vastly different (You can find them by going back through the Evg pages).
Nice attempt to try to discredit me though. And it seems like you have done the same amount of research and due diligence suggesting this account, and myself, are related to one another as you do with your investments. I.e. none.
Again, more lies from you on the cash raise front, but what should we expect? Your history is clear for all to see. You spend all your time on a share BB you aren't invested in, spreading lies and misinformation in an attempt to make yourself feel better about your loss here. It must have hit you hard, otherwise why would you stay here?
Going to be even worse for you when confirmation comes through that Stalicla have applied for IND from the FDA for STP2. Then even worse when IND is approved and Stalicla have to pay Evgen $5m. Or are you suggesting that is deal with Stalicla is fake and simply a rouse by the bod, by which they would be committing fraud and liable to severe prosecution? You still haven't explained why Stalicla won't pay Evgen when they are contractually obligated to do so if the milestones are reached.
OBD hardly have a proven product, no one is buying it and I don’t think they will until they have proven during large scale, randomised trials that it is more effective than the PSA test currently available. The sale figures to date prove this. OBD will continue to drop until finding is sorted and you’ll be even further in the hole. Again, you seem to have bought the hype without doing much due diligence. OBD is going to be yet another painful lesson for you. The question is, are you going to hang around there to deramp that share as well?
While a heavily invested bod can be a good thing, it means very little when investor confidence has been shattered and cash is needed. Many companies with a heavily invested bod end up in administration and simply having a bod invested doesn't mean they have PI interests at heart. OBD bod are at the mercy of investors and what IIs are prepared to pay for the impending cash raise. From the last update, I don’t expect it to be pretty for OBD.
And do you still stick by your pie in the sky valuation of £5.7 billion, £41 a share, while the Market Cap is barely over £30 million, 16p?
Is that you money munch ?
Pro you seemed to join in September 2022 at about the same time MM disappeared.
It's important because MM was a serial ramper and was singled out by many on here for being so. Similar to yourself Pro, he/she would post endlessly to bury any negative posts and round on anyone with a contrary view. Give it a few more months and Evgen will announce another placement that will decimat existing shareholder value. Admittedly shareholders can vote against, but the alternative will be oblivion.
OBD also need to raise cash, but the bods are heavily invested and will want to minimise shareholder pain. They have a proven product in the market, while Evgen are still at the basement level hoping Stalicla will pay out when it would be more cost effective to delay any payment until next year and then pick up the rights from the receivers for peanuts.
We'll see who ends up with egg on their face, but by then you'll be using a different alias and ramping another dead beat share
Sorry my bad, OBD dropped again today, so you actually need a 25700% rise.
Says the guy that valued OBD at over 150 times its prevailing share price, at £5.7 Billion, yes 5.7 billion pounds, making it a FTSE 100 behemoth. The delusion is unreal. I can almost guarantee OBD will NEVER be valued at £41 per share, unless a massive consolidation occurs. Only 20000% increased need Kingalf for your target and you have the audacity to suggest we’re in cuckoo land. Hahahahaha
The evidence suggests you're going to have egg on your face very soon. Looking forward to it.
If you think Stalicla will pay Evgen anything your all living in CCL.
Pro, your posts are reminiscent of Money Munch who used to continually ramp this up, and dissenting views were slapped down but all the while the share price continued to drop.
Obviously wouldn't expect them to be still using the same alias as they were completely discredited. Any connection ?
As for OBD, they have a product adopted by Bupa and are a million miles further down the road than Evgen.
Net buys going into the last trading hour is approximately 2 million shares. So a nice, steady rise today. Looks like the start of the re-rate has begun. We should get an RNS from AXA today/Monday and lets hope we see some additional news next week.
Decent buy at 9.48 for £18k today. Confidence is building. I want to start tweeting about this and introducing it to a couple of Telegram groups I'm in but I haven't finished building my position yet :)
GLA
CJ you are hilarious and a bit sad with that line of reasoning. If the board confirm phase 2 trials for this revolutionary approach to personalised testing and tailored treatments for autism spectrum disorder, affecting tens of millions with challenging health impacts, the sp will rerate in the near term and the whole proposal will attract media attention from the phase 1 data sets to begin with. Staclica have already had press coverage in quality papers for their work on dementia. Expect the same again for ASD. We will be moving into a completely different prospect over the next year or so. Don't expect these prices to stay this low if we get an RNS to confirm the information on the Staclica site.
The market will see the £5M Milestone payment from Stalicla as a big step towards its full immersion in the deal.
Also CJ, if this was about 'saving poor PI's from doom' or 'being a guardian angel' why don't you go onto boards of companies that literally have no product, no prospects of ever creating anything, have not made any tangible headway within their industry and use share holders as cash cows?
Evgen have demonstrated that they do, in fact, have a novel pharmaceutical compound and are making tangible progress with commercialising SFX-01. There are so many companies on aim that do nothing and are simply lifestyle companies for the bod, but Evgen is not one of them. So again, this highlights that you being here is personal.
Note I sometimes post on companies like Echo or Insp, both of which have no real product or assets and function solely to pay the directors. If you want to save PIs, go post on boards like that. This is not the case with Evgen, where SFX-01 is real and the deal with Stalicla is also very real.
I do not have to divulge personal information to you as frankly, my investment strategy is none of your business, nor is the number of shares I hold. I am tempted to buy more tomorrow though, as good news will be coming very soon.
Sure, the $5m milestone payment may only keep Evgen funded until 2026, but that is a very, very health runway for a clinical stage biopharma. But you do realise that there will be other developments between now and then? Or do you think that everything will suddenly stop?
P2 trials usually take between a few months and two years to complete, so I would expect the STP2 trials to be concluded/coming to an end by that point. We’ll know more once we see the trial details. There are also opportunities to licence out other indications during that time, which I am sure the bod are working on as we speak, not to mention the other trials and pre-clinical work the company are engaged with.
CJ,
OBD are out of cash in two months, with no current way of getting any non-dilutive funding in place before the cash runs out. EVG have until the end of the year, and we now have confirmation that Stalicla are still progressing with Phase 2 trails for SFX-01, despite the nonsense you and Kingalf have touted about them dropping it.
IND from the FDA is needed before P2 trials can commence, and Stalicla have, today, updated their website to suggest that both STP1 & STP2 will enter P2 this year. Therefore, one can reasonably conclude that they will apply/have applied for IND for STP2. Once this is granted, they will have to pay Evgen the $5m milestone payment.
I also did not state that OBD are doomed, but that the share price will likely drop back to the pre-hype price of 10p due to the poor sales figures, large cash burn and upcoming raise and lack of positive news flow in the coming months. I also said that until the sale figures pick up, the share price is likely to languish, all of which are very reasonable assumptions and prediction based on the evidence at hand.
You and Kingalf spread lies and miss-information in an attempt to discredit the company and damage the share price, touting the bod will dilute shareholder 70% when not needed, shown you have no real conceptual understanding of science or the pharma industry, believe your anecdotal evidence (know someone with autism, broccoli pill won’t work on them) is more valid than what the actual subject matter experts think, invested without doing due diligence and simply followed Kight, believe that SFX-01 is no different from sulforaphane you can buy on Amazon, believe another company could make their own SFX-01 despite it being very well patented and protected, believe AXA sold having had inside information which would be illegal, think Stalicla won’t carry forward SFX-01 despite there being evidence to the contrary. The list of rubbish and nonsense from you and Kingalf goes on and on.
I have significantly more posts here, on a share I am invested in than on the OBD board or any board where I have posted a negative comment. Approximately 75% of my posts from the past month are here. You have almost 80% of your posts on shares you’re not invested in. See the difference? You will notice that this is a common theme on our accounts, not just for this month.
As I said before, I don’t mind negative points of view if they are well reasoned. The lies and miss-information from yourself and Kingalf do not count as well reasoned. You are bitter and still highly emotional due to selling at a loss. That is why you spend all your time on the Evgen BB. You want this to fail, in an attempt to make yourself feel better about your loss. I see through you, and so do a lot of other genuine investors.
XxPoorInvestorxx it’s funny how you are critical of Kingalf and I for our criticism of EVG here, again mentioning why are we here when not invested yet I see you are on OBD giving it the same sort of criticism and predictions that the share is doomed.
I noticed you didn’t respond to my question as to what you are hoping to sell your shares for here.
Even if EVG get the $5.5m from Stalicla this year they are bound to find themselves back in this same position in 2026 with money running out again.
Fwiw IND from the FDA comes before phase 2 trials can begin, so expect news on the application very soon!
Were they waiting for AXA to exit or is it a coincidence? I did think Evg bod were waiting. I'd expect good news over the next few days/weeks and for the share price to rise accordingly.
Looks like the derampers droning on about fake placements may have egg of their face fairly soon!
Incredible news. They updated the website today by the looks of it! Going into P2 this year, so highly likely we will get the $5m from Stalicla this year. No placement needed!
Check it out for yourselves if you haven't already.
Link's not coming up but you can copy and paste.
Well someone is buying. Getting some half decent volume here. I've bought some more for my SIPP today. Encouraged by yhe web site update- says January 2024. And now states that STP1 and STP2 (EVG partnership) will go onto phase 2 clinical trials in 2024 for autism spectrum disorder.
Hoping to see an RNS to confirm in the coming days. I suspect that is why we're getting a gradual steady increase in volume- overwhelmingly buys, in the last few days.
GLA.
Kingalf
You do realise the market works only when there are both buyers and sellers? So of course people have been selling for years. However, AXA, the seller in question is fully out. Stop trying to twist what others are posting. Of course there will be others that sell in the future, no one has suggested otherwise. This thread, and the posts you are referring to are solely about AXA.
And as I have said many times before, no AXA do not have any inside information on an upcoming placement like you have suggested. More lies from you.
You seem a bit sore that your investment in OBD is down over 50% since the start of last week after suggesting it was worth £41 a share last year. I don't think anyone here has made such a ludicrous claim as suggesting EVG is worth 158 times its (then) market cap. But only a 25000% rise needed to hit your target.
OBD are in dire need of cash (£10m burn a year, out of cash by April) so discounted placement on the way. The CEO misled investors, the product sales have tanked, they haven't carried out large, randomised trials despite being told this would be needed by cancer research UK. Maybe you should go take your frustration out there? Also Odey sold their 17.94% stake in early November, so by your own logic they had inside information and knew the poor sale figures and are waiting for the discounted placement that will happen in the next month or so.
Its strange, both you and CJ spend more time here, a share you're not invested in, or have any intention on investing in, than shares you actually do own. Why is that I wonder?
That’s a laughable post, you have no idea why AXA have sold down their holding.
Furthermore, you have no idea on ‘what is definite’….
Biotech is a very interesting area to be invested, deals can be announced at any point, and clearly, the sudden increase in trading activity suggests others agree.
Let's be honest, the reason they've pulled out is that the next share placement will decimat existing shareholder value. These companies work on probability, and what is a definite is that Evgen will need more funds before year end. Admittedly Stalicla could pay out but the odds of that happening are way to high.
Please stop saying that the seller has finally finished, I've been hearing the same line for the last 2 years and each time a new seller joins.